Back Back
Gyn Conferences 2022

CME

Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: January 23, 2023

Expiration: January 22, 2024

CME/CE Information

Activity

Progress
1
Course Completed

Introduction

In the year 2022 alone, several clinical advances on new and emerging treatments, biomarkers, and molecular testing modalities were reported across the various annual meetings, including the Society of Gynecologic Oncology (SGO), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), International Gynecologic Cancer Society (IGCS), and European Society of Gynaecological Oncology (ESGO).

This module is a synopsis of key clinical trial data, landmark clinical trial updates, and new original research presented for ovarian, cervical, and endometrial cancers at the various global meetings and as highlighted by our experts: Elisabeth Diver, MD; Jubilee Brown, MD; Angeles Alvarez Secord, MD, MHSc; David Scott Miller, MD, FACOG, FACS; Alexandra Leary, MD, PhD; Domenica Lorusso, MD, PhD; Susana Banerjee, MBBS, MA, PhD, FRCP; Mansoor Raza Mirza, MD; Ignace Vergote, MD, PhD; and Isabelle Ray-Coquard, MD, PhD.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with gynecologic cancer do you provide care for in a typical month?
At ASCO 2022, Makker and colleagues presented data for the ongoing phase III SIENDO trial of maintenance selinexor vs placebo in patients with stage IV endometrial cancer following a partial response (PR) or complete response (CR) to 12 or more weeks of first-line therapy with taxane-carboplatin. Based on the data presented for that study, which of the following biomarkers should you assess to determine her likelihood of benefit from selinexor maintenance therapy?
At the 2022 ASCO Annual Meeting, Tewari and colleagues reported the subgroup analyses from the phase III KEYNOTE-826 trial of pembrolizumab combined with chemotherapy (CT) with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Based on data presented in that report, which of the following statements is correct regarding the various subgroups evaluated?
Your patient is a 56-year-old woman with history of endometrial cancer. She was previously treated with standard of care chemoradiation followed by systemic CT. She recently presents to you with recurrent endometrial cancer and residual peripheral neuropathy from previous chemoradiation and is currently receiving hydrochlorothiazide for hypertension and fluid retention in her lower extremities. Her PD-L1 CPS score is 2 (positive), and tumor testing showed MLH1 and PMS2 protein loss by immunohistochemistry. As you are planning your next steps for this patient, which of the following treatment strategies would be most appropriate to manage her recurrent endometrial cancer?

A patient arrives in your care with previously untreated advanced ovarian cancer with confirmed HRD. Her primary debulking surgery was incomplete. You proceed to treat her with platinum-based CT, and she achieves a PR.

You are now considering offering maintenance poly-ADP-ribose polymerase (PARP) inhibitor olaparib plus bevacizumab to maximize her PFS interval. Based on results presented at ESMO 2022 from the PAOLA-1 study, which of the following would you be most likely to mention regarding her potential outcome?